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Abstract
Background:  Dietary  trans-rich and interesterified fats were compared to an unmodified
saturated fat for their relative impact on blood lipids and plasma glucose. Each fat had melting
characteristics, plasticity and solids fat content suitable for use as hardstock in margarine and other
solid fat formulations.
Methods: Thirty human volunteers were fed complete, whole food diets during 4 wk periods,
where total fat (~31% daily energy, >70% from the test fats) and fatty acid composition were tightly
controlled. A crossover design was used with 3 randomly-assigned diet rotations and repeated-
measures analysis. One test fat rotation was based on palm olein (POL) and provided 12.0 percent
of energy (%en) as palmitic acid (16:0); a second contained trans-rich partially hydrogenated
soybean oil (PHSO) and provided 3.2 %en as trans fatty acids plus 6.5 %en as 16:0, while the third
used an interesterified fat (IE) and provided 12.5 %en as stearic acid (18:0). After 4 wk the plasma
lipoproteins, fatty acid profile, as well as fasting glucose and insulin were assessed. In addition, after
2 wk into each period an 8 h postprandial challenge was initiated in a subset of 19 subjects who
consumed a meal containing 53 g of test fat.
Results: After 4 wk, both PHSO and IE fats significantly elevated both the LDL/HDL ratio and
fasting blood glucose, the latter almost 20% in the IE group relative to POL. Fasting 4 wk insulin
was 10% lower after PHSO (p > 0.05) and 22% lower after IE (p < 0.001) compared to POL. For
the postprandial study the glucose incremental area under the curve (IAUC) following the IE meal
was 40% greater than after either other meal (p < 0.001), and was linked to relatively depressed
insulin and C-peptide (p < 0.05).
Conclusion: Both PHSO and IE fats altered the metabolism of lipoproteins and glucose relative to
an unmodified saturated fat when fed to humans under identical circumstances.
Background
Partially hydrogenated oils represent a means of removing
unstable polyunsaturated fatty acids (PUFA) from fats in
foods that require longer shelf life. Although semisolid at
room temperature, such products also technically repre-
sent a monounsaturated fatty acid (MUFA) replacement
for natural saturated fatty acids (SFA). Unfortunately, par-
tially hydrogenated oil represents the prime source of
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trans fatty acids (TFA) in the human diet. The negative
effects of TFA on lipoproteins have been widely publi-
cized [1], which led to inclusion of TFA on food labels by
various governments. Interesterification (fatty acid rand-
omization) of fat is fast becoming an alternate modifica-
tion technique, whereby insertion of saturated fatty acids
(SFA), typically as stearic acid (18:0), is employed to
harden an oil to a plasticity comparable to earlier trans fat
preparations or to hardness of a natural saturated fat. The
assumption has been that since 18:0, as consumed in nat-
ural fats at 2–4% of daily energy, is thought to have a neu-
tral effect on metabolism of cholesterol and lipoproteins
[2-4], the response to 18:0 at any level of intake and in any
triacylglycerol (TG) configuration would be neutral. How-
ever, like partial hydrogenation, the random insertion of
fatty acids on the glycerol backbone of the fat molecule
associated with chemical interesterification alters natural
TG structure, referred to as TG molecular species or TG-MS
[5]. Several studies reveal that altering dietary TG-MS, ie.
the natural position of specific fatty acids on the 3C glyc-
erol backbone (carbons designated as sn1, sn2, and sn3),
affects both lipoprotein metabolism and experimental
atherogenesis [6-9]. On the other hand, in certain situa-
tions serum lipid parameters were minimally affected
when the intake of randomized fat was modest or acute,
as in a single meal challenge with a modified fat contain-
ing altered TG-MS [10-12].
Accordingly, we hypothesized that chemically modified
vegetable oils, either partially hydrogenated or interester-
ified with abundant 18:0, might not have the same meta-
bolic impact as a naturally-configured saturated oil rich in
palmitic (16:0) + oleic (cis18:1) fatty acids. Three fats were
prepared as suitable hardstock for margarine and other
solid fat formulations. The natural fat was based on palm
olein (POL), used extensively for many food formulations
that still require a degree of fat saturation. Partially hydro-
genated soybean oil (PHSO) was included as the typical
example of a commonly used semisolid fat containing
geometric fatty acid isomers (cis or trans) of 18:1 and 18:2
(linoleic acid). The third fat was chemically interesterified
(IE), which randomly incorporated 18:0 into regular TG
molecules in soybean oil as an alternative hard fat for
food formulations. The primary focus was on blood lipids
and the lipoprotein profile in normolipemic humans,
with a secondary focus on blood glucose, insulin and C-
peptide.
Methods
Study design
The study, approved by the Program Advisory Committee
at the Malaysian Palm Oil Board, Bangi, Malaysia,
included informed signed consent by the human volun-
teers. The 3 dietary fats were compared using a crossover
design with 4 wk for each fat. Specifically, diets were iden-
tified as A, B, or C, and subjects were assigned to each in
random order until all three had been consumed by each
person. Thus, all three diets were available during each 4
wk treatment period, but individual assignment to each
was randomized to help negate possible carryover effects.
Subjects were advised to maintain their usual food intake
for all test rotations, which were identical in all aspects
except for the cooking fat. An electronic weighing balance
in the food service area was used to weigh food portions.
Blood samples were collected prior to beginning a test
period and twice during the last week (averaged as the ter-
minal value).
Within each 4 wk period, an identical subgroup of 19 sub-
jects participated in an acute postprandial challenge with
their respective test fat after 2 wk into each diet rotation.
Thus, volunteers were preconditioned with the test fat
during the 14 d prior to the postprandial challenge. After
an overnight fast of at least 12 h, volunteers reported to
the laboratory on the 15th morning. Body weight was
recorded and baseline fasted blood was drawn. Volunteers
then consumed a standardized test meal comprising
weighed portions of fried rice, fried potatoes, a slice of
papaya and tea. This test breakfast contributed a total of
53 g test fat, and consumption of this meal was completed
within 20 minutes of the first (baseline, 0 h) blood sam-
pling. Blood samples were then taken sequentially at 2, 4,
5, 6 and 8 h after the test meal was consumed. Volunteers
abstained from consuming any food during this 8 h
period, except bottled mineral water. They also refrained
from any strenuous activity during this interval. Following
the 8 h sample, volunteers received a fully cooked meal.
Study subjects
Eligibility criteria included absence of family history for
atherosclerosis or hypertension, as well as no use of
tobacco or alcohol or adherence to any weight loss pro-
gram or prescribed medication. A total of 11 healthy men
and 21 women (ave age 30 ± 8 y) were initially recruited
by advertisement among the 450 staff members at the
research facilities of the Palm Oil Board. One subject was
unable to comply with the dietary protocol and subse-
quently was dropped from the study, while another did
not complete the third rotation due to acute appendicitis.
The baseline demographics of the remaining 30 fasting
subjects who were recruited after initial screening and
who successfully completed the study were as follows
(mean ± SD): BMI 22 ± 4; body wt 56 ± 10 kg; blood lipids
(total cholesterol, 5.05 ± 0.53 mmol/L; LDL-C, 3.17 ±
0.51 mmol/L; HDL-C mmol/L, 1.48 ± 0.25 mmol/L; TG,
0.89 ± 0.30 mmol/L) and plasma glucose concentrations
(5.43 ± 0.29 mmol/L).Nutrition & Metabolism 2007, 4:3 http://www.nutritionandmetabolism.com/content/4/1/3
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Test fats
The 3 test fats (Table 1) included palm olein, as a natural
dietary fat (POL); a partially hydrogenated soybean oil
(PHSO); and an interesterified fat (IE) prepared in a 2-
step procedure. Palm olein is the liquid to semisolid oil
fraction obtained when palm oil is melted, followed by
rapid cooling to separate the upper liquid palm olein layer
(approximately 70%) from the lower solid stearin fraction
(approximately 30%) by a physical fat modification proc-
ess termed fractionation. POL contains more monoun-
saturated cis18:1 and less16:0 and 18:0 saturates relative
to original palm oil, which has more saturated 16:0 than
monounsaturated cis18:1. Both of the chemically modi-
fied fats, namely PHSO and IE, typically have less PUFA
and  cis18:1 content compared to native soybean oil
(SBO), but have higher solid fat content to confer more
plasticity and less susceptibility to rancidity. These three
fats each provided a TG structure and plasticity that
renders them suitable for use in common solid fat-con-
taining food formulations.
To prepare the IE fat, a first-step full hydrogenation of
refined SBO converted all unsaturated C18 fatty acids to
18:0, which was then blended with refined SBO and POL
that yielded the target fatty acid composition. The blend
was then subjected to chemical interesterification. To pre-
pare the PHSO, refined SBO was first partially hydrogen-
ated using standard catalytic hydrogenation to obtain a
targeted amount of TFA in the oil. For the final PHSO
composition, 40% of this partially hydrogenated SBO was
blended with 30% refined SBO and 30% POL.
The final test fats had the following slip melting points
(POL, 24.0; PHSO, 38.5; IE, 43.0°C). At 20°C the % sol-
ids equaled 20, 20 and 43 for POL, PHSO and IE, respec-
tively. The final test diet supplying POL provided 12.0
%en as 16:0, while the PHSO fat yielded a TFA content of
about 10% by wt, but contributing 3.2 %en as TFA plus
6.5 %en as 16:0 when incorporated into the final diet. The
zero-trans, IE-fat diet provided 12.5 %en as 18:0 (Table 1).
Test diets
Diets were prepared by a caterer who received detailed
instruction from the research dietitian about the menu
plan, portion size, and procedures for incorporating the
test fats. A uniform menu was utilized for all 3-diet peri-
ods, which differed only in the type of test fat incorpo-
rated. Three meals a day, comprising breakfast, lunch and
high tea were provided for the 4-wk period of each fat
rotation. The menu, which was used to prepare the meals
from Monday through Saturday noon, was constructed
according to a fixed meal plan: For breakfast, a rice or noo-
dle dish and a snack item cooked with the test fat was
served with either coffee or tea. Lunch included either fish
or chicken and 2 vegetables cooked with the test fat and
accompanied by rice and fruits along with either tea or
Table 1: Fatty acid profiles for individual test fats and overall FA profile of test diets
Fatty acid Test oils (% total fat) Test diets (% energy)
POL1 PHSO2 IE3 POL1 PHSO2 IE3
Saturates 44.05 29.32 58.61 13.66 9.09 18.17
12:0 0.23 0.22 nd 0.07 0.12 nd
14:0 0.90 0.40 0.29 0.28 0.17 0.09
16:0 38.82 21.18 17.66 12.03 6.53 5.48
18:0 4.10 7.19 40.25 1.27 2.18 12.48
20:0 nd 0.33 0.41 nd 0.09 0.13
Monounsaturates 43.77 41.06 18.90 13.57 12.41 5.86
18:1 (n-9) 43.77 41.06 18.90 13.57 12.41 5.86
Polyunsaturates 11.58 18.79 22.48 3.59 5.79 6.97
18:2 (n-6) 11.23 17.57 20.98 3.48 5.36 6.50
18:3 (n-3) 0.35 1.22 1.50 0.11 0.43 0.47
Total Trans nd 10.28 nd nd 3.19 nd
t18:1n9 nd 2.26 nd nd 0.70 nd
t18:1n11 nd 2.35 nd nd 0.73 nd
t18:1n13 nd 1.0 nd nd 0.31 nd
Unid nd 4.67 nd nd 1.45 nd
*P/S ratio 0.26 0.64 0.38 0.26 0.64 0.38
1POL, palm olein; 2PHSO, partially hydrogenated soybean oil; 3IE, interesterified fat (see text for details of fat composition)Nutrition & Metabolism 2007, 4:3 http://www.nutritionandmetabolism.com/content/4/1/3
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coffee. For high tea, a fried snack item incorporated the
test fat, which was served with either tea or coffee. Because
the subjects consumed their off-campus evening meal and
Sunday meals with their families at home, they were pro-
vided with the appropriate cooking fat to incorporate into
home meal preparations during each dietary period.
Fat and protein content of weighed food portions were
determined by established AOAC methods (22). Energy
value of the diets was determined with an automated
bomb calorimeter [C5000 IKA-Calorimeter system, IKA®
WERKE, KG, Germany]. Diets contained about 31 %en
from fat, 3.5–7 %en as linoleic acid, with each test fat pro-
viding more than 70% of the total fat under controlled
conditions. Dietary carbohydrate provided approximately
54 %en, and protein approximately15 %en. Carbohy-
drate content was indirectly estimated by difference of
total protein and total lipid mass from the dried mass of
the food samples. In addition, the use of the cooking fat
in homes (including Sundays) was recorded in a diary to
serve as an additional compliance marker. Overall, sub-
jects were blind to the test fat fed during each test rotation.
Blood samples
Twenty-ml blood samples were collected at baseline and
on days 28 and 29 of each test-fat rotation after overnight
fasting. For the postprandial study 12-ml blood samples
were collected (fasting baseline, and 2,4,5,6 and 8 h). Vac-
cutainer® tubes [Becton Dickinson Vaccutainer, NJ, USA]
with or without EDTA (0.117 ml of 15% EDTA) were used
for plasma and serum preparations, respectively. For
serum preparation, blood was allowed to clot at room
temperature for exactly 2 h. The Vaccutainer tubes were
then centrifuged at 3000 × g for 20 min at 4°C to separate
the serum or plasma, which was aliquoted for various
lipid and lipoprotein analyses, snap-frozen with liquid
nitrogen and stored at -80°C for subsequent analyses. To
reduce intra-assay variation, samples from all 3 arms of
dietary treatment were analyzed in a single batch.
Analyses of lipids and lipoproteins
Cholesterol and TG concentrations in plasma were ana-
lyzed by the enzymatic procedures of Allain et al [13] and
Nägele et al. [14], respectively. HDL-C determination was
based on a 2-step methodology, which required first pre-
cipitating LDL and VLDL from plasma with dextran and
magnesium sulfate and then assaying the supernatant
containing the HDL for cholesterol [15,16]. All assays
were performed using a Ciba-Corning 550 Express Auto-
analyzer [Ciba-Corning Diagnostics Corp., Oberlin,
Ohio, USA]. All reagents, calibrators and controls were
supplied by Bayer Corp. (Tarrytown, NY, USA), HDL-C
precipitant by Chiron Diagnostics Corp. [E. Walpole, MA,
USA/Bayer Corp., Tarrytown, NY, USA]. LDL-C and VLDL-
C were calculated using Friedewald's equations [18].
TG-MS composition was determined by reverse-phase
HPLC. The fat blends were used directly and not subjected
to further purification prior to the analysis. The mobile
phase was acetone/acetonitrile (Merck) at a gradient com-
position beginning with 65% acetone and increasing to
85% acetone in 30 min. The mobile phase flow rate was
1.5 mL/min. Two commercially packed Genesis C18
HPLC columns (15 cm length × 4.6 mm i.d.) of 4 um par-
ticle size (Jones Chromatography, Mid Glamorgan,
United Kingdom) were used to separate the TG-MS. The
TG-MS were detected by an Evaporative Light Scatter
Detector, ELSD. Individual peaks were identified by com-
paring the retention times with those of pure TG-MS
standards and common vegetable oils of known TG-MS
composition [17].
Determination of plasma glucose, serum insulin and C-
peptide
Plasma glucose was assessed from frozen samples by the
glucose oxidase method, a 2-step enzymatic procedure
[19]. A reagent kit for the enzymatic procedure, SERA-
PAK® Glucose (which was fully Bayer Corporation, Tarry-
town, NY, USA) was used in the analysis, which was auto-
mated using the Ciba-Corning 550 Express Autoanalyzer
(Ciba-Corning Diagnostics Corporation, Ohio, USA).
Serum insulin was measured [20] for 0 wk, 4 wk, and
postprandial samples by automated immunoassay with
an IMMULITE 1000 Analyzer (Euro/DPC Limited Diag-
nostics Products Corporation, Los Angeles, Ca.) and
expressed as uU/ml. Circulating C-peptide was measured
in postprandial serum as an index of insulin secretion
[21]. Samples were diluted (1:4) prior to immunoassay
with the IMMULITE 1000 Analyzer. All components
(chemiluminescent substrate, controls, standards and
diluent) for the insulin and C-peptide immunoassays
were supplied in IMMULITE kits. Results are expressed as
pmol/L.
Compliance measurements
General compliance to diet was assessed by body weight
changes and the comparison between the fatty acid com-
position of diets eaten and plasma TG. In the first
instance, weight was recorded for every subject at baseline
and at weekly intervals for each test rotation. This ensured
that food intake was adequate and that weight fluctua-
tions were minimized between the test-fat rotations.
Plasma TG fatty acid composition of was determined for
all subjects at the end of each test rotation. Total lipids
were extracted from plasma and subjected to thin-layer
chromatography to separate TG and cholesteryl esters
[22,23]. In addition, fatty acids from diets as eaten were
assessed following Soxhlet extraction and conversion of
extracted lipids into fatty acid methyl esters for analysis by
gas chromatography [Perkin-Elmer Autosystem, Perkin-Nutrition & Metabolism 2007, 4:3 http://www.nutritionandmetabolism.com/content/4/1/3
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Elmer, Norwalk, CT]. Test fats themselves were assayed
directly after conversion to methyl esters [22,23]. Results
from gas chromatography of fatty acids were obtained as
percentage composition (by weight), calculated by refer-
ence to standards. The fatty acid profile of meals con-
sumed by the subjects served to check whether the
research diets achieved fatty acid targets, while the plasma
TG fatty acids served to check compliance with the
research protocol.
Statistical analysis
The crossover design enabled each subject to serve as his/
her own control. The Statistical Package for Social Sci-
ences, SPSS® for Windows™ application (Version 11.0,
SPSS Inc., Chicago, USA) was used for all required statisti-
cal analyses. The mean of values for days 28 and 29 was
treated as the end of the study period. Univariate analysis
was performed for linearly independent pair-wise com-
parisons between baseline and end values for plasma lip-
ids, lipoproteins, glucose, and insulin, as well as for the
percent change in the measured parameters for each die-
tary treatment. Multivariate analyses for repeated meas-
ures (ANOVA), using the general linear model, was
performed for all time × diet interactions for blood glu-
cose, insulin and C-peptide parameters following each
postprandial test fat challenge. Corrected models used
against baseline values were taken as true measures of
change occurring during the post-absorptive period result-
ing from dietary treatment. Univariate analysis was per-
formed for linearly independent pair-wise comparisons of
incremental area-under-the-curve (IAUC) data for the 8-h
postprandial period calculated by the trapezoidal rule
[25]. Post-hoc analyses included Bonferroni's adjustment
for multiple paired comparisons of estimated marginal
means as well as Duncan's test for homogeneity of the
effects generated by the test fat treatments. Significance
was set at P < 0.05 for all evaluated measures.
Results
Weight
Initial body weights were not altered during the experi-
ment, as weight fluctuations between test fat rotations
were comparable (<0.25 kg gained per fat) and not statis-
tically different [data not shown].
Diet intake
Based on weighed food portions and diary records, the
daily energy consumed by subjects averaged between
2100 and 2200 kcal/d. Protein intake averages were
between 80–89 g/d (about 16 %en), fat between 73–77 g/
d (about 31 %en), and carbohydrate between 283–292 g/
d (about 53 %en) for the 3 diet periods. Food intake pat-
terns were consistent and similar between treatments
[data not shown].
Fatty acid and TG-MS profiles
As expected, random interesterification of fully hydrogen-
ated soybean oil with regular soybean oil led to a signifi-
cant number of TG-MS in the IE test fat having 18:0 in sn2.
By contrast, the POL test fat was represented by TG-MS
having significant unsaturated cis18:1 at sn2. Specifically,
the TG-MS compositions for the natural POL and IE fats
(Table 2) revealed that the sn2 (number 2 carbon of glyc-
erol) was occupied by 18:0 or 16:0 in about 15% and 6%,
respectively, of the TG molecules in IE. Thus, 21% of the
TG molecules in IE had a saturated fatty acid at sn2. By
contrast, no TG molecules with sn2-18:0 were detected in
POL; and only 9 % of all TG molecules in POL had a sat-
urated fatty acid at sn2 (as 16:0). Thus, the total saturated
fatty acid content at sn2 was more than twice as great for
IE fat (sn2-18:0+16:0). By contrast, 87% of TG molecules
in POL had cis18:1 at sn2, while only 55% TG molecules
in IE fat had cis18:1 at sn2. Surprisingly, only 1% of TG in
POL had 18:2 at sn2, compared to 21% for the IE fat; and
about 20% of TG molecules in POL had 18:2 at sn1,3,
whereas 42% of the TG molecules in IE had 18:2 at these
end carbons. Because standards for the TFA-containing TG
molecules separated by this HPLC method are not availa-
ble, one can only assume that partial hydrogenation of
SBO generated substantial numbers of TFA at sn2, because
most of the monounsaturated fatty acids in PHSO (which
would include trans18:1) are reportedly located at sn2
[24].
Compliance check for test fat consumption deduced that
specific FA of plasma TG (Table 3) reflected the TG fatty
acid profile of both the test fat as well as the total diet fat
(Table 1) for each fat rotation. Thus, plasma 16:0 and 18:2
were highest and lowest, respectively, in dietary and
plasma TG during POL; 18:0 was highest in plasma TG
during IE intake; and trans18:1 was only detected in
plasma TG after feeding the PHSO diet.
Lipid and lipoprotein changes
Plasma analysis revealed that HDL-C and LDL-C were the
only two lipid parameters significantly affected by dietary
treatment, with TC and TG unperturbed (Table 4). After
adjusting for multiple comparisons between dietary treat-
ments, plasma HDL-C was significantly lower (p < 0.001)
both during the PHSO (-8%) and IE (-9%) diet treatments
compared to POL. Dietary fat also affected absolute
change in LDL-C, with the concentration after the PHSO
being 7% greater than POL (P < 0.05). The IE diet effect
was intermediate and not significantly different from
either POL or PHSO (Table 3).
Ratios derived from absolute measurements of TC, LDL-C
and HDL-C at the end of each dietary treatment (Table 3)
reveal that PHSO and IE treatments both increased the
TC/HDL-C ratio by about 10% relative to the POL (P <Nutrition & Metabolism 2007, 4:3 http://www.nutritionandmetabolism.com/content/4/1/3
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0.001), but did not differ from each other. The LDL-C/
HDL-C ratio was similarly increased by the two modified
fats, with differences being about 15% greater than the
POL diet (P < 0.001).
Glucose, insulin, and C-peptide
4 wk fasting data
Fasting plasma glucose at the end of each test fat period
(Table 4), revealed a significantly higher value after IE
treatment than after either POL or PHSO (p < 0.001). Glu-
cose also increased modestly after the PHSO diet relative
to POL (p < 0.05). Individual fasting glucose data meas-
ured at entry and the end of each test fat period revealed
that plasma glucose for every subject increased during the
IE diet period (Fig 1).
Fasting serum insulin at 4 wk varied greatly among indi-
viduals, but univariate analysis revealed significantly
Table 3: Fatty Acid Composition (%) of Plasma Triacylglycerol
Fatty acid Test diets
POL1 PHSO2 IE3
14:0 1.4 ± 0.5a 1.4 ± 0.4b 1.1 ± 0.4a,b
16:0 29.5 ± 2.9a,b 27.2 ± 2.8a 26.6 ± .1.8b
16:1n7 3.8 ± 1.1 3.6 ± 1.4 3.5 ± 1.0
18:0 3.3 ± 0.8a 3.4 ± 0.5b 5.3 ± 2.4a,b
18:1 43.4 ± 4.2a,b 37.1 ± 3.0a,c 40.3 ± 3.3b,c
t18:1n9 nd 2.8 ± 0.6 nd
t18:1n11 nd 0.8 ± 0.3 nd
18:2 16.1 ± 4.4a,b 20.6 ± 5.1a 20.1 ± 2.8b
18:3 0.7 ± 0.4a 1.2 ± 0.5a,b 0.7 ± 0.2b
20:4n6 0.9 ± 0.3 1.0 ± 0.3 0.9 ± 0.2
22:6 1.3 ± 0.7 1.7 ± 0.7 1.3 ± 0.6
Values are means ± SD (n = twice per rotation)
1POL, palm olein; 2PHSO, partially hydrogenated soybean oil; 3IE, interesterified fat (see text for details of fat composition)
a,b,c means with common superscripts differ, p < 0.05; nd = not detectable.
Table 2: Major Triglyceride Molecular Species (%) in POL and IE fats *
TG Species POL IE
LLnLn ND 2.00
LLLn ND 0.85
LLL ND 0.78
PLLn ND 0.42
OLL 0.20 2.63
PLL 0.90 4.64
OOL 0.70 2.00
SLL ND 12.47
PPL 8.60 3.42
OOO 2.70 0.48
SOL ND 13.79
SOS ND 15.84
SOO 1.5 4.62
POS 4.2 15.25
PPS ND 2.92
SSO ND 10.81
SSS ND 3.76
POP 39.5 ND
POO 32.2 ND
POL 9.3 ND
TOTAL 99.80 96.68
L = linoleic; Ln = Linolenic; O = oleic; P = palmitic; S = stearic
ND, not detected
*Triglyceride species for PHSO are not reported since they were not possible to assess due to the complexity of the TG species arising from the 
the lack of authentic standards to identify the various trans fatty acid isomers present.Nutrition & Metabolism 2007, 4:3 http://www.nutritionandmetabolism.com/content/4/1/3
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lower insulin values after IE (p < 0.001) with a tendency
for PHSO to be lower (p < 0.10) relative to POL. Thus, the
percent change for PHSO (-10%) was approximately half
that observed for IE (-22%) relative to POL (Table 4).
Consequently the average fasting 4 wk-insulin for each fat
treatment was inversely related to the respective glucose
concentration, ie. the most elevated fasting glucose fol-
lowing the IE period was associated with the lowest 4 wk
fasting insulin, whereas the insulin value following
PHSO, like glucose, was intermediate between POL and
IE.
Postprandial responses
In the postprandial meal challenge after 2 wk on the diet,
plasma glucose became significantly elevated 6 h after the
IE meal compared to POL and PHSO (p < 0.001). The lat-
ter two fats displayed similar postprandial glucose
dynamics with both returning to baseline by 6 h (Fig 2a).
Based in part on the slightly higher fasting glucose values
for IE at the beginning of the postprandial test, the incre-
mental area under the curve (IAUC) for glucose during the
8 h IE fat challenge was approximately 40–45% greater (p
< 0.001) than the two other fats (Fig 2b).
To explore insulin dynamics postprandially, both insulin
and C-peptide were measured throughout the 8 h post-
prandial period. Both parameters peaked sharply at 2 h,
and C-peptide was directly related to the insulin concen-
tration at this time interval (Fig 3a and 3b). The 2 h insu-
lin was significantly lower after both the PHSO (p < 0.05)
and IE (p < 0.05) challenge compared to POL, while C-
peptide was significantly lowered only by IE (13.2 ± 6.6
pmol/L; p < 0.05)) compared to either POL (16.0 ± 7.4
pmol/L) or PHSO (15.6 ± 6.4 pmol/l). POL and PHSO
did not differ from each other.
Discussion
Interesterification and lipoproteins
Based on previous data concerning TG-MS affecting lipid
metabolism [5,6], a primary objective of this study was to
compare the relative response by plasma lipoproteins to
structural differences in dietary fatty acids and TG-MS
introduced by partial hydrogenation (production of TFA)
or interesterification with 18:0. In the final analysis, 15%
of TG-MS in IE had 18:0 at sn2, compared to none of the
TG-MS in POL having sn2-18:0. Furthermore, IE had 2.5-
times more SFA at sn2 than POL; and although we were
not able to make the assessment with our assay, many of
the sn2-FA in PHSO are reportedly trans18:1 with essen-
tially no SFA at sn2 (24). Thus, our data support previous
observations that structural differences between fatty
acids and TG-MS can perturb lipoprotein metabolism, eg.
when TFA or 16:0 are introduced at sn2 in fat molecules
where MUFA or PUFA normally reside [9-11,26]. Simi-
larly, our data confirm that compared to a naturally struc-
tured fat, random interesterification of a polyunsaturated
dietary fat with 18:0 alters its TG-MS as well as the lipo-
protein metabolism encountered during its consumption
[9,27].
Both partial hydrogenation and IE represent substitutes
for naturally saturated dietary fats. Our study directly
addressed the efficacy of those substitutions by comparing
unmodified TG-MS in a naturally occurring saturated fat,
Table 4: Fasting plasma lipid, lipoprotein cholesterol, glucose, and insulin concentrations after 4 wk of test diets
Test diet
POL1 PHSO2 IE3
Total cholesterol (mmol/L) 4.93 ± 0.58 5.03 ± 0.69 4.89 ± 0.63
HDL-C (mmol/L) 1.43 ± 0.24a,b 1.32 ± 0.24a 1.30 ± 0.22b
% change vs POL -- -7.6 ± 6.7 -9.1 ± 6.7
LDL-C (mmol/L) 3.08 ± 0.54c 3.30 ± 0.63c 3.20 ± 0.61
% change vs POL -- 7.2 ± 11.5 3.8 ± 9.7
VLDL-C (mmol/L) 0.42 ± 0.16 0.41 ± 0.16 0.40 ± 0.13
Triacylglycerol (mmol/L) 0.91 ± 0.34 0.88 ± 0.35 0.86 ± 0.28
TC/HDL-C 3.53 ± 0.68a,b 3.91 ± 0.82a 3.88 ± 0.83b
% change vs POL -- 10.8 ± 8.5 9.7 ± 9.0
LDL-C/HDL-C 2.23 ± 0.59a,b 2.59 ± 0.69a 2.56 ± 0.74b
% change vs POL -- 16.0 ± 12.1 14.7 ± 13.4
Plasma glucose (mmol/L) 5.62 ± 0.48a,c, 5.91 ± 0.58b,c 6.67 ± 0.70a,b
% change vs POL -- 5.1 ± 9.6 18.7 ± 11.3
Plasma insulin (uIU/mL) 10.11 ± 4.67a 9.12 ± 3.92c 7.93 ± 3.18a,c
% change vs POL --- -9.7 ± 26.0 -21.6 ± 22.2
Mean ± SD ; n = 30
1POL, palm olein; 2PHSO, partially hydrogenated soybean oil; 3IE, interesterified fat (see text for details of fat composition)
a,b means with common superscripts differ, p < 0.001. c p < 0.05Nutrition & Metabolism 2007, 4:3 http://www.nutritionandmetabolism.com/content/4/1/3
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POL, with PHSO and IE. Approximately equal amounts of
total SFA (14–18 %en) were provided during the two sat-
urated fat test periods, ie. with POL and IE diets, while the
TFA-rich diet provided about 12 %en as SFA plus TFA.
Both modified fats included specific alterations in sn2-FA.
Although total plasma cholesterol was minimally affected
by the 3 diets, the distribution of cholesterol among lipo-
proteins was altered. PHSO (representing unnatural
incorporation of trans18:1 at sn2) elevated LDL; and both
PHSO and IE (with 18:0 atypically present at sn2) lowered
HDL relative to the naturally-structured POL with mainly
cis18:1 and a lesser amount of 16:0 at sn2. The increased
LDL/HDL ratio following consumption of PHSO was also
significant and typical of the pattern reported during
trans-fat consumption [8,9,28-30]. It is noteworthy that in
at least two of those studies when 18:0 was interesterified
into unsaturated oils and compared to trans18:1, cis18:1,
or IE fat rich in 18:2 [8,9], both the added 18:0 in IE fat as
well as trans18:1 from partial hydrogenation were found
to raise LDL and lower HDL. Such results are similar to
our findings, where the naturally occurring fat structure in
POL served as the control fat.
The high proportion of test fat (>70%) in our diets was
coupled with specific exchanges between fatty acids and
modified TG-MS. The comparison was focused on 16:0 in
a natural fat, 18:0 from a randomized fat, and 16:0 plus
about one-third the amount of TFA from partial hydro-
genation. This comparison between relatively high intakes
of specific SFA and TFA enhanced the potential to detect
an effect induced by the concomitant change in dietary
TG-MS. Despite the fact that the TFA diet provided 50%
more 18:2 than POL, and favorably increased 18:2 among
plasma TG fatty acids, the TFA diet still exerted a more
negative impact on plasma lipoproteins. One would pre-
dict that reducing 18:2 in the TFA diet to that of the con-
trol diet would have rendered the TFA diet even less
desirable [9]; or alternatively, had the POL diet been
adjusted to contain an equivalent amount of 18:2 as the
other two diets, it should have performed even more favo-
Individual fasting glucose values are depicted at entry and after 4 wk on each test fat Figure 1
Individual fasting glucose values are depicted at entry and after 4 wk on each test fat. The rise was 3% for POL, 9% for PHSO, 
and 22% for IE.
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rably [31]. To this point, it is noteworthy that POL, with
its superior metabolic effect, had the lowest total dietary
18:2 content and only 1% of its TG molecules having sn2-
18:2 with most 18:2 at sn1,3. These collective data imply
that a lack of 18:2 at sn2 is not as problematic as the
abnormal insertion of SFA (or TFA) in that location.
These data also support the previous conclusion [30] that
TFA are more detrimental than either of the two main SFA
(16:0 and 18:0) that they were designed to replace in food
products, at least gram for gram when considering lipo-
protein metabolism. It is also clear that SFA as 16:0 in the
TG-MS of natural POL was an improvement (even with
less 18:2 present) compared to an approximately equal
mass of 18:0 randomly inserted into SBO in the form of
the IE fat, leading to a significant amount of 18:0 at sn2.
This indicates that 18:0 should not be considered a neu-
tral SFA, at least when randomized into sn2 or if it
becomes the major dietary SFA. By the same token, others
have shown that 16:0 randomized into the sn2 position
raises LDL cholesterol in men when compared to natural
palm oil [10], a fat in which sn2 is largely cis18:1, similar
to the situation with POL here. Thus, as these several stud-
ies demonstrate, manipulating dietary TG-MS can nega-
tively influence plasma lipoproteins, even though the
exact degree of TG modification required and the mecha-
nism are unclear.
Modifying sn2 fatty acids, particularly by introducing a
saturated fatty acid at this site, would seem a likely candi-
date for distorting lipoprotein metabolism. Caprenin, an
artificial fat with randomized behenic acid (22:0), exerts a
negative impact on human LDL/HDL metabolism similar
to that seen with TFA [32], and both 22:0 and TFA elicited
effects similar to randomized 18:0 observed in this study
and in two previous studies where IE fat was fed [8,9].
Long chain (18-22C) saturated fatty acids are relatively
uncommon in natural fats, with 18:0 representing the
a (top) Postprandial plasma insulin was significantly higher for  POL than either other fat after 2 h (mean ± SE) Figure 3
a (top) Postprandial plasma insulin was significantly higher 
for POL than either other fat after 2 h (mean ± SE). Fig 3b 
(below) Postprandial plasma C-peptide was significantly 
lower 2 h after the IE meal (mean ± SE).
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most prevalent at intakes <2–4% daily energy. Further-
more, 18:0 in natural fats is usually esterified at sn1 and
sn3 on glycerol, as in beef tallow and cocoabutter [33].
Artificial insertion of 18:0 at sn2 during random interest-
erification, along with the shear mass of 18:0 consumed
(12 %en), may have been problematic in the current study
and previously [8,9]. The mass of 18:0 consumed may be
critical because a large intake (7 %en), from sheanut but-
ter was found to depress HDL similar to Caprenin [34].
Sheanut butter is reported to have 18% of sn2 as SFA
(mostly 18:0), or 3× the amount of sn2-SFA present in
cocoabutter [33], a fat that does not appear to affect lipo-
protein metabolism adversely [4,12]. Although consump-
tion of 12 %en as 18:0 would not be feasible from natural
fats, it is possible to envision an exaggerated intake via
structurally modified fats resulting from the growing
impetus to eliminate TFA from the diet. The incorporation
of 18:0 has seemed especially appealing since 18:0 from
natural fats often has been considered neutral in its
impact on cholesterol metabolism [2-4,35].
Glucose perturbations
Among studies on the metabolic effects of randomized fat
involving 18:0, metabolism of glucose and insulin has not
been addressed. Considering global trends in obesity,
insulin resistance, and diabetes, which are often associ-
ated with the metabolic syndrome, our observation that
altered dietary TG-MS may adversely influence glucose
metabolism warrants attention. From epidemiological
data on the association between TFA intake and diabetes
[36] one might have anticipated the TFA-induced rise in
glucose observed after 4 wk. Even though previous exper-
iments involving TFA in humans found no effect on glu-
cose metabolism other than postprandial insulin
hypersecretion [37,38], those studies reported essentially
no change in the fasting lipoprotein profile either, which
is somewhat atypical. In our study IE fat had less effect
than the TFA-rich PHSO on lipoproteins, but proved more
deleterious for glucose metabolism, suggesting that mod-
ified TG-MS, from either trans-rich or IE fats, was a factor.
After 4 wk on each diet, fasting insulin was inversely
related to glucose, ie. insulin was moderately lower after
PHSO (-10%, ns) and substantially lower after IE (-20%,
p < 0.001) compared to POL, while glucose was signifi-
cantly elevated by both modified fats (about 5% and 20%,
respectively). The elevated 4 wk fasting glucose following
IE was foreshadowed by the 40% greater glucose IAUC
observed during the 8 h postprandial challenge with the
IE test meal. The patterns of lower plasma insulin (IE,
PHSO) and C-peptide (IE) postprandially following the
test meal challenge with the two modified fats relative to
POL, suggests that reduced insulin secretion, rather than
insulin resistance, accounted for the higher glucose values
observed with modified fats. The 20% rise in fasting glu-
cose with IE was clinically important, as well, since it rose
to a range that could be considered prediabetic after only
4 wk [39]. These results appear to be in contrast to the ele-
vated serum insulin and insulin resistance typical of obes-
ity and type 2 diabetes associated with the metabolic
syndrome [40,41].
Our findings suggest that altered dietary fat composition
or TG-MS influenced insulin secretion to impact glucose
metabolism negatively. Others have reported initially
lower blood glucose coupled with sharply higher initial
insulin secretion 20–60 min postprandially in subjects
fed a single meal of IE palm oil compared to natural palm
oil [11]. Postprandial insulin hypersecretion also
occurred in diabetic subjects fed extreme intakes of TFA or
SFA compared to cisMUFA [38]. Thus, a connection seems
to exist between dietary fat composition and insulin secre-
tion. The link may include the n-3 PUFA content of fats.
For example, it is noteworthy that dietary 18:3n-3 and
long chain n-3 PUFA have been linked to production of
intestinal GLP-1 [42], which enhances insulin secretion. It
may prove ironic that partial hydrogenation of vegetable
oils, or interesterification with 18:0, are implemented in
part to remove 18:3n-3 and improve product shelf life,
even though fats modified in this manner may inadvert-
ently suppress insulin secretion after their prolonged con-
sumption. Interesterification resulting in high intake of
18:0, including sn2-18:0, appeared to accentuate the neg-
ative effect observed with the TFA diet. In reference to
insulin metabolism, both 18:0 and TFA fed at high levels
(8% en) also induced inflammatory markers [43] that are
associated with diabetes [44].
It is not apparent whether the observed alteration in glu-
cose and lipoprotein metabolism represents a fatty acid
effect per se or modification of TG-MS. For example, ear-
lier work in gerbils traced saturated fat intake and inositol
deficiency to a lack of PUFA needed structurally for phos-
phatidyl inostitol (PI) synthesis required for fat secretion
by intestinal mucosal cells [45]. Since PI is also involved
in beta-cell secretion of insulin [46], PI structure or avail-
ability may be a consideration in the mechanistic aspect of
our current clinical observations. Extreme SFA consump-
tion (usually to the exclusion of dietary PUFA) is typically
linked to insulin resistance [47], while other studies have
reported that dietary SFA enhances insulin secretion more
than dietary PUFA [48], a possibility suggested by our
findings where POL diet had the lowest P/S ratio. Clarifi-
cation is needed, but careful scrutiny of the dietary PUFA
load as it affects dietary TG-MS and phospholipid synthe-
sis related to insulin dynamics is warranted [6].
In past investigations, glucose metabolism has not
received the intense scrutiny afforded lipoproteins in
most studies involving dietary fat. The present results link-Nutrition & Metabolism 2007, 4:3 http://www.nutritionandmetabolism.com/content/4/1/3
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ing TFA and 18:0- rich IE fats with abnormal metabolism
of glucose suggest that it would be prudent to determine
the biologically tolerable mass of 18:0 that can be incor-
porated in diets as IE fats.
Conclusion
A natural saturated fat, palm olein, was compared to two
forms of modified replacement fats, one containing trans
fatty acids, the other interesterified with 18:0. Both modi-
fied fats adversely altered metabolism of plasma lipopro-
teins and blood glucose in humans. Further investigation
is warranted before interesterification is disseminated as
the process of choice for replacing partial hydrogenation
as a primary means for hardening vegetable oils for use in
foods.
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